Pharvaris N.V. Ordinary Shares (PHVS)

Price$28.78

Favorite Metrics

Price vs S&P 500 (26W)22.82%

Price vs S&P 500 (4W)5.53%

Market Capitalization$2.20B

All Metrics

Book Value / Share (Quarterly)$4.90

P/TBV (Annual)4.24x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.48

Price vs S&P 500 (YTD)2.37%

EPS (TTM)$-3.53

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-3.53

EPS (Annual)$-3.50

ROI (Annual)-64.58%

Cash / Share (Quarterly)$5.27

ROA (Last FY)-58.28%

EBITD / Share (TTM)$-3.38

ROE (5Y Avg)-42.63%

Cash Flow / Share (Annual)$-2.48

P/B Ratio5.84x

P/B Ratio (Quarterly)5.56x

Net Income / Employee (Annual)$-2

Net Interest Coverage (TTM)-45.75x

ROA (TTM)-63.99%

EPS Incl Extra (Annual)$-3.50

Current Ratio (Annual)10.11x

Quick Ratio (Quarterly)10.01x

3-Month Avg Trading Volume0.20M

52-Week Price Return130.90%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.81

52-Week High$29.85

EPS Excl Extra (Annual)$-3.50

CapEx CAGR (5Y)32.70%

26-Week Price Return26.81%

Quick Ratio (Annual)10.01x

13-Week Price Return11.65%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.11x

Enterprise Value$1,524.337

Revenue / Employee (Annual)$0

Cash / Share (Annual)$5.27

3-Month Return Std Dev42.49%

Net Income / Employee (TTM)$-2

ROE (Last FY)-64.77%

Net Interest Coverage (Annual)-9.83x

EPS Basic Excl Extra (Annual)$-3.50

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.53

ROI (TTM)-70.57%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.69

Price vs S&P 500 (52W)101.07%

Year-to-Date Return5.01%

5-Day Price Return7.65%

EPS Normalized (Annual)$-3.50

ROA (5Y Avg)-39.06%

Month-to-Date Return3.15%

Cash Flow / Share (TTM)$-3.69

EBITD / Share (Annual)$-3.38

LT Debt / Equity (Annual)0.17x

ROI (5Y Avg)-42.52%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-3.53

P/TBV (Quarterly)4.13x

P/B Ratio (Annual)5.56x

Book Value / Share (Annual)$4.90

Price vs S&P 500 (13W)10.96%

Beta-2.64x

Revenue / Share (TTM)$0.00

ROE (TTM)-70.76%

52-Week Low$12.01

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.33

4.26

About

Pharvaris is a late-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist designed to prevent and treat hereditary angioedema (HAE) attacks. The company has demonstrated positive efficacy data in Phase 2 studies and is currently enrolling pivotal Phase 3 trials for both treatment and prevention indications.